A conditional replication-competent adenoviral vector, AD-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis

Cancer Research

Volumn 61, Issue 16, 2001, Pages 6012-6019

  Matsubara, Shigeji ^a   Wada, Yoshitaka ^a   Gardner, Thomas A ^a,b   Egawa, Masayuki ^a   Par, Moon Soo ^a   Hsieh, Chia Ling ^a   Zhau, Haiyen ^a   Kao, Chinghai ^a,b   Kamidono, Sadao ^c   Gillenwater, Jay Y ^a   Chung, Leland W K ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b Indiana Cancer Pavilion   (United States)

^c KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOCALCIN; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; GENE THERAPY; HUMAN; HUMAN ADENOVIRUS; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; NUDE MOUSE; OSTEOBLAST; PRIORITY JOURNAL; PROSTATE CANCER; VIRUS RECOMBINANT; VIRUS REPLICATION; XENOGRAFT;

ADENOVIRUS E1A PROTEINS; ADENOVIRUSES, HUMAN; ANIMALS; BONE NEOPLASMS; CELL DIVISION; GENE THERAPY; GROWTH INHIBITORS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; MICE, SCID; NEOPLASMS, HORMONE-DEPENDENT; OSTEOCALCIN; OSTEOCLASTS; PROMOTER REGIONS (GENETICS); PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; STROMAL CELLS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035881263     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
2. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer
3. In situ gene therapy for adenocarcinoma of the prostate: A phase 1 clinical trial
4. Osteocalcin directed gene therapy for prostate cancer bone metastasis
5. Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization
6. Ad5CMVp53 gene therapy for locally advanced prostate cancer-where do we stand?
7. The application of an anti-angiogenic gene (thrombospondin-I) in the treatment of human prostate cancer xenografts
8. Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model
9. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer
10. Immunotherapy of prostate cancer in the Dunning rat model: Use of cytokine gene modified tumor vaccines
11. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: Suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model
12. Viral vector delivery in solid-state vehicles: Gene expression in a murine prostate cancer model
13. Poxvirus vectors: Orphaned and underappreciated
14. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy
15. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts
16. Exploiting stromal-epithelial interaction for model development and new strategies of gene therapy for prostate cancer and osteosarcoma metastasis
17. Permanent phenotypic and genotypic changes of prostate cancer cells cultured in a 3-dimensional rotating wall vessel
18. Reciprocal mesenchymal-epithelial interaction affecting prostate tumor growth and hormonal responsiveness
19. A novel gene therapeutic strategy co-targeting tumor epithelium and stroma
20. Vitamin-K dependent formation of bone GLA protein (osteocalcin) and its function
21. Regulated expression of the bone-specific osteocalcin gene by vitamins and hormones
22. Identification and characterization of two proximal elements in the rat osteocalcin gene promoter that may confer species-specific regulation
23. Bone tissue specific transcription of the osteocalcin gene: Role of an activator osteoblast-specific complex, and suppressor Hox proteins that bind the OC box
24. Msx-2/Hox 8.1: A transcriptional regulator of the rat osteocalcin promoter
25. Transcriptional synergism between the vitamin D3 receptor and other nonreceptor transcription factors
26. DNA sequences downstream from the vitamin D response element of the rat osteocalcin gene are required for ligand-dependent transactivation
27. Characterization of an enhancer required for 1.25-dihydroxyvitamin D3-dependent transactivation of the rat osteocalcin gene
28. Osf2/Cbfa1: A transcriptional activator of osteoblast differentiation
29. Two distinct osteoblast-specific cis-acting elements control expression of a mouse osteocalcin gene
30. Association between an oncogene and an anti-oncogene: The adenovirus E1A proteins bind to the retinoblastoma gene product
31. LNCaP model of human prostatic carcinoma
32. Delivation of androgen-independent human LNCaP prostatic cancer cell subline: Role of bone stromal cells
33. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer
34. Androgen-repressed phenotype in human prostate cancer
35. Establishment and characterization of a human prostatic carcinoma cell line (PC-3)
36. Isolation of a human prostate carcinoma cell line (DU145)
37. Establishment of human carcinoembryonic antigen-producing colon adenocarcinoma cell line
38. A fetal rat urogenital sinus mesenchymal cell line (rUGM): Accelerated growth and conferral of androgen-induced growth responsiveness upon a human bladder cancer epithelial cell line in vivo
39. Growth of 293 cells in suspension culture
40. Specific histologic and cytogenetic evidence for in vivo malignant transformation of murine host cells by three human prostate cancer cell lines
41. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3
42. Tn5 mutagenesis of the transforming genes of human adenovirus type 5
43. Generation and identification of recombinant adenovirus by liposome-mediated transfection and PCR analysis
44. Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models
45. Establishing human prostate cancer cell xenografts in bone: Induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines
46. Vascular pericytes express osteogenic potential in vitro and in vivo
47. Noncollagenous bone matrix proteins, calcification, and thrombosis in carotid artery atherosclerosis
48. Ablation of murine prostate utilizing Ad-OC-TK/GCV treatment: A potential gene therapy strategy for the treatment of benign prostatic hyperplasia (BPH)
49. Replication-selective adenoviruses as oncolytic agents
50. Prostate cancer gene therapy: Herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models
51. Adenoviral-mediated transfer of a heat-inducible double suicide gene into prostate carcinoma cells
52. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficiency
53. In vivo gene therapy for α-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene
54. Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene
55. Melanoma-specific cytotoxicity induced by a tyrosinase promoter-enhancer/herpes simplex vires thymidine kinase adenovirus
56. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein
57. Widening the therapeutic window of thymidine kinase/GCV gene therapy with a tumor-restricted promoter: Osteocalcin based TK gene therapy for osteosarcoma
58. Inhibition of hydroxyapatite crystal growth by bone-specific and other calcium-binding proteins
59. Dissociation between bone resorption and bone formation in osteopenic transgenic mice
60. Increased bone formation in osteocalcin-deficient mice
61. Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers
62. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease
63. In vivo amplification of the androgen receptor gene and progression of human prostate cancer
64. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence
65. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer
66. Chemogene therapy: Osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model
67. In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy
68. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone
69. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer
70. Chemotherapy of advanced prostatic carcinoma
71. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer